Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive treatments for talquetamab-related oral toxicity
ISRCTN72589181Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of talquetamab in multiple myeloma (MM) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Occurrence of taste dysfunction, Occurrence of severe hypogeusia and 2 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN72589181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72589181.